People · Operator
Named in public records as an officer, director or promoter · active 2020–2020 · Biotechnology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Dyne Therapeutics, Inc. | — | Biotechnology | Series D+ | $115.7M | $4.6B | 2020 |
Dirk Kersten at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Dirk Kersten on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Jason Rhodes | 1 | 3 |
| David Lubner | 1 | 3 |
| Richard Scalzo | 1 | 2 |
| Joshua Brumm | 1 | 2 |
| Edward Hurwitz | 1 | 2 |
| Romesh Subramanian, Ph.D. | 1 | 1 |
| Lawrence Klein, Ph.D. | 1 | 1 |
| Jonathan McNeill, M.D. | 1 | 1 |
| Catherine Stehman-Breen, M.D. | 1 | 1 |
| Oxana Beskrovnaya, Ph.D. | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.